The Fda not long ago acquired extra leverage more than pharmaceutical businesses. Will it use it? : NPR

In response to the regulating of pharmaceuticals companies and the lack of competition in the market, the Food and Drug Administration (FDA) has recently gained more power over companies in the pharmaceutical industry. The question on everyone’s mind is whether the FDA will use this power to their advantage.

For years, the market for prescription drugs in the United States has been dominated by a handful of players, creating a lack of competition, and causing prices to skyrocket. The FDA’s decision to acquire more authority over pharmaceuticals companies is being seen as a signals to these companies that it will no longer stand for high prices and a lack of fair competition.

The new powers for the FDA are expected to make it easier for generic drugs to enter the market, leading to lower prescription drug prices for consumers. It is also expected to allow the FDA to better regulate drug advertising, and to be able to more closely monitor drugs on the market for safety and efficacy.

It is not yet clear how the FDA will use its new power. It could take a hands-off approach, letting the marketplace determine prices and rewards, or a more proactive role, taking a larger role in the interpretation of data and pricing strategies. What is clear is that the FDA is committed to ensuring that consumers are getting quality and affordable medication.

One thing to keep in mind is that the FDA’s new powers will have an effect not only on the way prescription drugs are priced, but also on the types of drugs approved. So, while the FDA has more leverage over pharmaceutical companies now, how it uses this leverage could shape the future of medicine in the United States. [ad_1]

[ad_2]

Source connection